- Details
Thrombogenics will pay €1 million to Galapagos to further explore integrin antagonists as treatment for diabetic retinopathy.
Read more: Deal struck to develop integrin antagonist treatment
- Details
A new study shows that the new low-add versions of the 1-piece Tecnis multifocal IOL yield greater patient satisfaction and a higher rate of spectacle independence compared to the older +4.00 Tecnis multifocal lens.
Read more: New low-add multifocal IOLs yield higher patient satisfaction
- Details
The companies will jointly develop a combination of the angiopoietin2 antibody nesvacumab and the anti-VEGF aflibercept for the treatment of wet AMD and diabetic macular edema.
Read more: Regeneron, Bayer to develop AMD combination therapy